Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jun 8, 2010


David Weitz and John Boyce are among the co-founders of GnuBio, a Harvard University spinout that plans to develop fast and inexpensive microdroplet-based DNA sequencing technology (see article, this issue).

Weitz is a professor of physics and applied physics at Harvard. He is also a co-founder of microdroplet firm RainDance Technologies. Previously, he was a professor of physics at the University of Pennsylvania, and before that, a physicist at Exxon Research and Engineering. He holds a PhD in physics from Harvard.

Boyce is the co-founder of consulting firm Delphi Bio and co-head of business development, sales, and marketing at Affomix. Prior to that, he was head of business development and scientific collaborations at Helicos BioSciences, and before that, he was senior director of commercial development at Parallele Biosciences, now part of Affymetrix, and senior director of sales and marketing at Sequenom.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.